Trials / Completed
CompletedNCT04566003
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
Phase 1 Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to compare tau targeted radiotracers \[18F\]GTP1 and \[18F\]PI-2620 or \[18F\]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]GTP1 | Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer. |
| DRUG | [18F]PI-2620 | Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer. |
| DRUG | [18F]MK-6240 | Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer. |
Timeline
- Start date
- 2020-10-26
- Primary completion
- 2023-06-27
- Completion
- 2023-06-27
- First posted
- 2020-09-28
- Last updated
- 2023-07-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04566003. Inclusion in this directory is not an endorsement.